In the future, patients using GLP-1 patches with GLP-1 or GIP/GLP-1 molecules may experience the side effects of GLP-1 agonist drugs, such as constipation, diarrhea, vomiting, abdominal pain, gallbladder disease, pancreatitis, kidney injury, and hypoglycemia
It makes sense that thats where the mechanism of action is. The brain was always involved, he says, but these new drugs are helping researchers zero in on the brain as a center for regulating energy in and energy out. Appetitethe drive to eatis biologically motivated by three core sensations: hunger, fullness and reward
Our team educates and guides we never pressure you into treatments
Award-winning scientist Professor Jens Juul Holst, alongside co-authors Professor Sten Madsbad, Professor Jens Meldgaard Bruun, and Novo Nordisk Foundation CEO Mads Krogsgaard Thomsen, trace the scientific breakthroughs and clinical advances that have made GLP-1 therapies, such as Ozempic and Wegovy, essential tools for improving blood sugar control and promoting meaningful, lasting weight loss in patients worldwide